Topfond is located at Zhumadian, Henan, China, a place which is called as the hinterland of Central plains, the bosom land of China. Founded in 1969, Topfond is a large comprehensive pharmaceutical company which combines the production, R＆D, and trading of APls, intermediates, and western and Chinese traditional finished dosage forms, has 16 subsidiary companies, 1 R＆D center, and 80 representative offices nationwide.

Among the current 5000 employees, 2100 hold junior college or higher educational background. Topfond is one of the key-521 companies authorized by the State Economic and Trade Commission of China, and a New＆High-Tech company certified by Ministry of Science and Technology and Chinese Academy of Science. Topfond now produces 11 categories of finished dosage forma covering more than 360 varieties and specifications of products. It has the first class equipments and the computer application ranks the top advanced level in China. Marketing network covers all over the country and the market occupancies of Fleroxacin(dosage forms), Acetylspiramycin, Venoruton and Chlortetracycline Feed Grade are 85%, 55%, 40% and 30% separately. Meanwhile, Topfond is also sparing no efforts on developing international market. Main APIs (Spiramycin, erythromycin thiocyanate, alprazolam, etc.) and some finished dosage forms have been exported to more than 20 countries and areas in Western Europe, North Africa, South America, Southeast Asia. Topfond has made itself a leading player in Chinese pharmaceutical industry with constant go-aheadism spirit, well-knit internal work, and great development potential for years. Topfond has won the titles‘National Advanced company unit in Metrology’,‘National Excellent pharmaceutical enterprise’, ‘Henan provincial May 1st Labor Reward’,‘New＆High-Tech company in Torch Plan of Henan Province’,etc.

Facing the future, Topfond will make itself a large pharmaceutical group combining R＆D, industry and trading, while base itself on Henan and radiate to the whole country, and hold strong international competition participation capability, by continuing the work of having sharing outside, holding, and capital reorganizing and expanding the activities in medicine logistics.